Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload
about
Advances in iron chelation therapy: transitioning to a new oral formulation.Deferasirox-induced iron depletion promotes BclxL downregulation and death of proximal tubular cells.A complicated disease: what can be done to manage thalassemia major more effectively?Optimizing the diagnosis and the treatment of iron overload diseases.Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?Cardiac complications in thalassemia major.The era of comparable life expectancy between thalassaemia major and intermedia: Is it time to revisit the major-intermedia dichotomy?Current recommendations for chelation for transfusion-dependent thalassemia.β-Thalassemia.Safety profiles of iron chelators in young patients with haemoglobinopathies.How we manage iron overload in sickle cell patients.The new era of chelation treatments: effectiveness and safety of 10 different regimens for controlling iron overloading in thalassaemia major.Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload.Increased sympathovagal imbalance evaluated by heart rate variability is associated with decreased T2* MRI and left ventricular function in transfusion-dependent thalassemia patients.Deferasirox: Over a Decade of Experience in Thalassemia
P2860
Q33879123-992B8B36-DE26-4644-BB70-B07CCB6B0DA6Q37615232-0EBACCC7-4A4E-480C-AACE-CDC997FCB15BQ38607875-099F6907-AF81-4BCA-9C42-E7EA990E774FQ38631586-33D0EEBA-DC6A-4152-B9E3-C6BDB38CFBF4Q38727988-5F26421A-65DB-4CA3-AE71-3C052E88D4CBQ38768594-F8B0A00F-3E10-4700-88F3-6E859A65AC52Q38810873-46A1FA1F-852D-48F8-92A2-94A2757E109AQ38836184-6CD4BD10-3D3F-4B40-BC49-22F05A941CDCQ38998151-9E74C0DC-8EB9-492D-975C-14F8539BB131Q39022073-D0682D79-582C-4CA3-9164-E32171F6FFE3Q39179372-C73BD8F3-BA81-4535-96D0-CC86E0DF4CABQ39260564-01051707-A8A9-49B9-ADA0-12BE9EB52E57Q47864152-C14316F2-B3BA-43B8-99AE-187E31A064B1Q48539558-8B740656-146F-4207-93D6-982592AF3842Q58701123-9D158902-000B-4701-9ABA-0B9F064114F2
P2860
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Effects of deferasirox-deferox ...... re transfusional iron overload
@ast
Effects of deferasirox-deferox ...... re transfusional iron overload
@en
type
label
Effects of deferasirox-deferox ...... re transfusional iron overload
@ast
Effects of deferasirox-deferox ...... re transfusional iron overload
@en
prefLabel
Effects of deferasirox-deferox ...... re transfusional iron overload
@ast
Effects of deferasirox-deferox ...... re transfusional iron overload
@en
P2093
P2860
P50
P1433
P1476
Effects of deferasirox-deferox ...... re transfusional iron overload
@en
P2093
Amal El-Beshlawy
Antonis Kattamis
HYPERION Investigators
Junwu Shen
Mohsen Elalfy
Niculae Constantinovici
Vip Viprakasit
Yesim Aydinok
Yurdanur Kilinç
P2860
P304
P356
10.1182/BLOOD-2014-07-586677
P407
P577
2015-05-01T00:00:00Z